Approval of generic Dostinex

Editorial Checklist Reviewed
Jul 10 2007NewsGuard 100/100 Score

Barr Pharmaceuticals, Inc. has announced that its subsidiary Barr Laboratories, Inc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Pharmacia and Upjohn Company's Dostinex (cabergoline) tablets, 0.5 mg.

The Company's Abbreviated New Drug Application (ANDA) was acquired from Teva Pharmaceuticals Industries Ltd. in connection with the acquisition of Ivax by Teva in January 2006. The Company plans to launch a product that is supplied by Teva in September 2007.

Dostinex had annual sales of approximately $68 million for the twelve months ended May 2007, based on IMS sales data.

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Source:

http://www.barrlabs.com/

Posted in: Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Study finds thousands of food-contact chemicals in humans, raising safety concerns
Key triggers for food allergies in children after organ transplants
Updated Food Compass 2.0 improves food health ratings using new diet data
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
Ultra-processed food linked to weight gain and lower well-being in adolescents
High levels of microplastics found in prostate tumors, possibly linked to take-out food
Living in food deserts during early childhood raises long-term obesity risk
Six common flying with food allergies myths

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood